Pelham Barton

7.8k total citations · 1 hit paper
116 papers, 5.4k citations indexed

About

Pelham Barton is a scholar working on Economics and Econometrics, Epidemiology and General Health Professions. According to data from OpenAlex, Pelham Barton has authored 116 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Economics and Econometrics, 28 papers in Epidemiology and 27 papers in General Health Professions. Recurrent topics in Pelham Barton's work include Health Systems, Economic Evaluations, Quality of Life (32 papers), Smoking Behavior and Cessation (13 papers) and Healthcare cost, quality, practices (9 papers). Pelham Barton is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (32 papers), Smoking Behavior and Cessation (13 papers) and Healthcare cost, quality, practices (9 papers). Pelham Barton collaborates with scholars based in United Kingdom, United States and Netherlands. Pelham Barton's co-authors include Stirling Bryan, Paresh Jobanputra, Tracy Roberts, A Fry-Smith, Sue Jowett, Yen‐Fu Chen, Amanda Burls, Joanna Coast, Suzanne Robinson and Lazaros Andronis and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Pelham Barton

112 papers receiving 5.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial

2015 293 citations Jane Daniels, Lee Middleton et al. Health Technology Assessment profile →

Peers

Countries citing papers authored by Pelham Barton

Since Specialization

Citations

This map shows the geographic impact of Pelham Barton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pelham Barton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pelham Barton more than expected).

Fields of papers citing papers by Pelham Barton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pelham Barton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pelham Barton. The network helps show where Pelham Barton may publish in the future.

Co-authorship network of co-authors of Pelham Barton

This figure shows the co-authorship network connecting the top 25 collaborators of Pelham Barton. A scholar is included among the top collaborators of Pelham Barton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pelham Barton. Pelham Barton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cost-effectiveness of Left Ventricular Assist Devices (LVADs) as destination therapy in the UK: An economic modelling study 2024 ·PLoS ONE ·Tuba Saygın Avşar, Louise Jackson, Pelham Barton, Sophie Beese, Hoong Sern Lim, David Quinn, Malcolm J Price, (unknown)	0
2	Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for advanced heart failure: systematic review and economic evaluation 2024 ·Health Technology Assessment ·Sophie Beese, Tuba Saygın Avşar, Malcolm J Price, David Quinn, Hoong Sern Lim, Janine Dretzke, Chidubem B. Ogwulu, Pelham Barton, Louise Jackson, David Moore	3
3	Exome Sequencing for Prenatal Detection of Genetic Abnormalities in Fetal Ultrasound Anomalies: An Economic Evaluation 2020 ·Fetal Diagnosis and Therapy ·(unknown), E Quinlan-Jones, Dominic McMullan, Eamonn R. Maher, Matthew E. Hurles, Pelham Barton, Mark D. Kilby	13
4	Early Economic Evaluation to Identify the Necessary Test Characteristics of a New Typhoid Test to be Cost Effective in Ghana 2019 ·PharmacoEconomics - Open ·(unknown), Andrew Sutton, Clare Davenport, Pelham Barton	6
5	Integrating Qualitative Techniques in Model Development: A Case Study Using the Framework Approach 2018 ·Applied Health Economics and Health Policy ·(unknown), Clare Davenport, Andrew Sutton, Justice Nonvignon, Pelham Barton	1
6	Primary care REFerral for EchocaRdiogram (REFER) in heart failure: a diagnostic accuracy study 2016 ·British Journal of General Practice ·Clare Taylor, Andrea Roalfe, (unknown), Richard Hobbs, (unknown), Pelham Barton, Jonathan J Deeks, Deborah McCahon, Martín Cowie, G C Sutton, (unknown), Jonathan Mant, Theresa A. McDonagh, Lynda Tait	31
7	Testing and Treating Women after Unsuccessful Conservative Treatments for Overactive Bladder or Mixed Urinary Incontinence: A Model-Based Economic Evaluation Based on the BUS Study 2016 ·PLoS ONE ·Ilias Goranitis, Pelham Barton, Lee Middleton, Jonathan J Deeks, Jane Daniels, Pallavi Latthe, Arri Coomarasamy, (unknown), (unknown), (unknown), Tracy Roberts	6
8	A Systematic Review of Research Guidelines in Decision-Analytic Modeling 2015 ·Value in Health ·(unknown), Pelham Barton, Sue Jowett, Andrew Sutton	32
9	Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party 2015 ·Rheumatology and Therapy ·Jason Madan, A. E. Ades, Pelham Barton, Laura Bojke, Ernest Choy, Philip Helliwell, Paresh Jobanputra, Ken Stein, Andrew Stevens, Jonathan Tosh, Suzanne Verstappen, Allan Wailoo	8
10	Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling 2013 ·Health Technology Assessment ·Catherine Meads, Peter Auguste, Clare Davenport, (unknown), Sudha Sundar, Marta Kowalska, (unknown), Peter Guest, Shakila Thangaratinam, Pierre L. Martin‐Hirsch, E Borowiack, Pelham Barton, Tracy Roberts, Khalid S. Khan	44
11	Cost-effectiveness of sentinel lymph node biopsy vs inguinofemoral lymphadenectomy in women with vulval cancer 2013 ·British Journal of Cancer ·Andrew Sutton, Pelham Barton, Sudha Sundar, Catherine Meads, Adam N. Rosenthal, Peter Baldwin, Khalid S. Khan, Tracy Roberts	12
12	Optimisation of thrombolysis treatment: where to start? 2012 ·International Journal of Stroke ·(unknown), James P Sheppard, (unknown), Pelham Barton, Richard J. McManus, (unknown)	1
13	Protocol for an observation and implementation study investigating optimisation of the management of stroke and transient ischaemic attack (TIA) 2012 ·BMJ Open ·James P Sheppard, Ruth M. Mellor, (unknown), Pelham Barton, Amunpreet Boyal, Sheila Greenfield, Sue Jowett, Jonathan Mant, Tom Quinn, Satinder Singh, Richard J. McManus, (unknown)	7
14	Promoting smoking cessation in Pakistani and Bangladeshi men in the UK: pilot cluster randomised controlled trial of trained community outreach workers 2011 ·Trials ·Rachna Begh, Paul Aveyard, Penney Upton, Raj Bhopal, Martin White, Amanda Amos, R.J. Prescott, Raman Bedi, Pelham Barton, Monica Fletcher, Paramjit Gill, (unknown), Aziz Sheikh	22
15	Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study 2011 ·The Lancet ·Kate Lovibond, Sue Jowett, Pelham Barton, Mark J. Caulfield, Carl Heneghan, Richard Hobbs, James Hodgkinson, Jonathan Mant, Una Martin, Bryan Williams, David Wonderling, Richard J. McManus	230
16	Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: cost effectiveness analysis 2011 ·BMJ ·Tracy Roberts, A Tsourapas, Lee Middleton, Rita Champaneria, Jane Daniels, Kevin Cooper, Siladitya Bhattacharya, Pelham Barton	79
17	Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation 2009 ·Health Technology Assessment ·Yen‐Fu Chen, Sue Jowett, Pelham Barton, K Malottki, Christopher Hyde, J. Simon R. Gibbs, (unknown), A Fry-Smith, Jamie Roberts, David Moore	125
18	Promoting smoking cessation in Bangladeshi and Pakistani male adults: design of a pilot cluster randomised controlled trial of trained community smoking cessation workers 2009 ·Trials ·Rachna Begh, Paul Aveyard, Penney Upton, Raj Bhopal, Martin White, Amanda Amos, R.J. Prescott, Raman Bedi, Pelham Barton, Monica Fletcher, Paramjit Gill, (unknown), Aziz Sheikh	5
19	'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis 2008 ·Health Technology Assessment ·(unknown), Martin Connock, Pelham Barton, A Fry-Smith, Paul Aveyard, David Moore	103
20	Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation 2008 ·Health Technology Assessment ·Yen‐Fu Chen, Paresh Jobanputra, Pelham Barton, Sara E. Bryan, A Fry-Smith, Gerald J. Harris, Robert Taylor	256

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact